Development and Validation of a Prognostic Signature Based on Immune Genes in Cervical Cancer

Yu Chen; Hao Lin; Ya-Nan Pi; Xi-Xi Chen; Hu Zhou; Yuan Tian; Wei-Dong Zhao; Bai-Rong Xia

doi:10.3389/fonc.2021.616530

Frontiers in Oncology (Mar 2021)

Development and Validation of a Prognostic Signature Based on Immune Genes in Cervical Cancer

Yu Chen,
Hao Lin,
Ya-Nan Pi,
Xi-Xi Chen,
Hu Zhou,
Yuan Tian,
Wei-Dong Zhao,
Bai-Rong Xia

Affiliations

Yu Chen: Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life, Sciences and Medicine, University of Science and Technology of China, Hefei, China
Hao Lin: Graduate School, Benbu Medical College, Benbu, China
Ya-Nan Pi: Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China
Xi-Xi Chen: Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life, Sciences and Medicine, University of Science and Technology of China, Hefei, China
Hu Zhou: Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life, Sciences and Medicine, University of Science and Technology of China, Hefei, China
Yuan Tian: Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life, Sciences and Medicine, University of Science and Technology of China, Hefei, China
Wei-Dong Zhao: Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life, Sciences and Medicine, University of Science and Technology of China, Hefei, China
Bai-Rong Xia: Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life, Sciences and Medicine, University of Science and Technology of China, Hefei, China

DOI: https://doi.org/10.3389/fonc.2021.616530
Journal volume & issue: Vol. 11

Abstract

Read online

BackgroundCervical cancer is one of the most common types of gynecological malignancies worldwide. This study aims to develop an immune signature to predict survival in cervical cancer.MethodThe gene expression data of 296 patients with cervical cancer from The Cancer Genome Atlas database (TCGA) and immune-related genes from the Immunology Database and Analysis Portal (ImmPort) database were included in this study. The immune signature was developed based on prognostic genes. The validation dataset was downloaded from the Gene Expression Omnibus (GEO) database.ResultThe immune signature namely immune-based prognostic score (IPRS) was developed with 229 genes. Multivariate analysis revealed that the IPRS was an independent prognostic factor for overall survival (OS) and progression-free survival (PFS) in patients with cervical cancer. Patients were stratified into high IPRS and low IPRS groups, and those in the high IPRS group were associated with better survival, which was validated in the validation set. A nomogram with IPRS and stage was constructed to predict mortality in cervical cancer.ConclusionsWe developed a robust prognostic signature IPRS that could be used to predict patients’ survival outcome.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords